Proactive Investors - Run By Investors For Investors

Optibiotix Health - Rapidly Transitioning to Commercial Phase

Optibiotix Health - Rapidly Transitioning to Commercial Phase
  • Preventing and treating diseases through the modulation of the microbiome is one of the most exciting frontiers of healthcare, and a fast growing market
  • OptiBiotix Health PLC (LON:OPTI), an innovative life sciences company focused on human microbiome, is rapidly transitioning from product development to the commercial stage with early revenues and commercial deals with major corporates including Tata and DSM
  • Underpinned by a strong scientific rationale and clinical studies, OptiBiotix Health PLC (LON:OPTI) products help managing significant health problems as weight loss, high cholesterol and hypertension
  • OptiBiotix Health PLC (LON:OPTI) commercial push is currently directed towards the rapidly growing consumer health market
  • A rich deal pipeline is likely to translate in material revenue growth (£1mln+) within 12 months

OptiBiotix is rapidly transitioning from being focused on product development to the market launch of their products.

We understand that the Company is actively pursuing a wide range of commercial deals, including licensing, profit sharing and distribution agreements, across multiple

geographies. In the last couple of years, OptiBiotix has already entered into development and commercial deals with several international companies, including KSF (Slimfast), Tata (x2), DSM and Sacco.

We are confident that the current rich deal pipeline will trigger a significant revenue uptake in the coming quarters. Based on our understanding, a typical commercial deal could generate annual revenue in the £250,000 - £500,000 range; we also note that larger deals in the multi-million range are within the Company's current reach.

We expect the income generated by the ongoing commercial expansion to provide the resources needed to accelerate OptiBiotix commercial push, including the potential acquisition on new IP and products.

From a financial perspective, OptiBiotix, with approx. £1.9mln of cash at the end of May 2017 and an estimated cash burn of c. £90k/month, is self-funded well into 2018, excluding any potential income from new deals.

Full report is available via Capital Network website
View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Researches

November 30 2017

WideCells Group PLC ( LON:WDC) was originally set-up in 2012 in Portugal, as a provider of stem cell storage services for the Portuguese and Spanish markets. In 2016 the company was listed on the London Stock Exchange, raising £1.7mln - net of fees, largely used to establish a new research and storage facility in Manchester, UK and to support the ongoing international expansion.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use